Evaluation of serum galectin-3 levels at Alzheimer patients by stages: a preliminary report

ConclusionIn conclusion, serum galactin-3 levels may be associated with AD and maybe a potential biomarker for the identification of disease in the early stages. In future years, serum galectin-3 levels may become an important biomarker and therapeutic agent for chronic neurodegenerative diseases such as AD.

http://link.springer.com/10.1007/s13760-020-01477-1

Source: Acta Neurologica Belgica - August 26, 2020 Category: Neurology Source Type: research